National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

doxercalciferol
A synthetic analog of vitamin D with potential antineoplastic activity. In the liver, doxercalciferol is converted to its biologically active vitamin D metabolites, which control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. Through interaction with specific receptor proteins in target tissues, these vitamin D metabolites act directly on osteoblasts to stimulate skeletal growth, and on the parathyroid glands to suppress PTH synthesis and secretion. This agent has also been shown to inhibit the growth of retinoblastomas, and may exhibit some antiproliferative activity against prostate cancer cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Hectorol
Chemical structure names:
  • (1alpha,3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol
  • 1-alpha-hydroxyvitamin D2



Previous:donepezil hydrochloride, Dopar, dornase alfa inhalation solution, dovitinib lactate, Dox-SL
Next:doxifluridine, DOXIL, doxorubicin hydrochloride, doxorubicin prodrug INNO-206, doxorubicin-GnRH agonist conjugate AEZS-108

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov